Vandria announced topline results from its first-in-human Phase 1 trial of VNA‑318, a small-molecule therapy for potential treatment of Alzheimer’s disease. The findings—presented at the 18th Clinical Trials in Alzheimer’s Disease (CTAD) meeting in San Diego—showed the drug was well tolerated, penetrated the brain, and produced a statistically significant, dose-dependent change in a key plasma biomarker, suggesting successful target engagement.
According to Vandria, VNA-318 is orally bioavailable and brain-penetrant, designed to modulate a novel target tied to mitochondrial function and inflammation. In preclinical models the drug demonstrated both immediate pro-cognitive effects (improved memory and learning) and long-term disease-modifying effects (reduced neuroinflammation and toxic protein aggregation, improved mitochondrial function).
In the Phase 1 trial (VNA-318-01), 92 healthy male participants received single or multiple ascending doses under a randomized, double-blind design. The company reported no serious adverse events or discontinuations, pharmacokinetics consistent with once-daily dosing, and a clear, dose-dependent shift in the plasma biomarker (p < 0.001). Cerebrospinal fluid measurements in a cohort confirmed that VNA-318 reaches therapeutic concentrations in the central nervous system.
Given these results, Vandria plans to advance VNA-318 into Phase 2 proof-of-concept trials. The firm also noted the compound’s potential to address other CNS conditions and age-related disorders, as well as its broader pipeline targeting non-CNS diseases such as lung, liver, and muscle conditions.
